Submitted:
19 July 2024
Posted:
22 July 2024
You are already at the latest version
Abstract

Keywords:
1. Introduction
2. Results and Discussion
2.1. Process for 3-methyl-1H-indazol-6-amine (8)
2.2. Process for N,3-dimethyl-1H-indazol-6-amine (9) via Reductive Amination
2.3. Process for N,2,3-trimethyl-2H-indazol-6-amine (5)
3. Materials and Methods
3.1. General Information
3.2. Synthetic Procedure
3-Methyl-1H-indazol-6-amine (8)
N,3-Dimethyl-1H-indazol-6-amine (9)
N,2,3-Trimethyl-2H-indazol-6-amine (5)
N,N,2,3-Tetratramethyl-2H-indazol-6-amine (5’)
4. Conclusions
Supplementary Materials
Author Contributions
Funding
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- European Medicines Agency (2012), EPAR summary for the public, Votrient, Procedure No. EMEA/H/C/001141.
- Kumar, R.; Knick, V.B.; Rudolph, S.K.; Johnson, J.H.; Crosby, R.M.; Crouthamel, M.C.; Hopper, T.M.; Miller, C.G.; Harrington, L.E.; Onori, J.A.; et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007, 6, 2012–2021. [Google Scholar] [CrossRef]
- Keisner, S.V.; Shah, S.R. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 2011, 71, 443–454. [Google Scholar] [CrossRef]
- McCormack, P.L. Pazopanib: a review of its use in the management of advanced renal cell carcinoma. Drugs 2014, 74, 1111–1125. [Google Scholar] [CrossRef]
- Harris, P.A.; Boloor, A.; Cheung, M.; Kumar, R.; Crosby, R.M.; Davis-Ward, R.G.; Epperly, A.H.; Hinkle, K.W.; Hunter, R.N., 3rd; Johnson, J.H.; et al. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem 2008, 51, 4632–4640. [Google Scholar] [CrossRef]
- Mei, Y.C.; Yang, B.W.; Chen, W.; Huang, D.D.; Li, Y.; Deng, X.; Liu, B.M.; Wang, J.J.; Qian, H.; Huang, W.L. A novel practical synthesis of pazopanib: An anticancer drug. Lett. Org. Chem. 2012, 9, 276–279. [Google Scholar]
- Boloor, A.; Cheung, M.; Davis, R.; Harris, P.A.; Hinkle, K.; Mook, R.A. Jr.; Stafford, J.A.; Veal, J.M. Pyrimidineamines as angiogenesis modulators. US7105530B2. 2006.
- Mei, Y.C.; Yang, B.W. The regioselective alkylation of some indazoles using trialkyl orthoformate. Indian J. Heterocycl. Chem. 2017, 27, 275–280. [Google Scholar]
- Frizzo, C.P. , Alkyl Orthoformate: A versatile reagent in organic synthesis. Synlett., 2009, 2009, 1019–1020. [Google Scholar] [CrossRef]
- Kim, D.J.; Oh, K.H.; Park, J.K. A general and direct synthesis of imidazolium ionic liquids using orthoesters. Green Chemistry, 2014, 16, 4098–4101. [Google Scholar] [CrossRef]






| Entry | Ratio (SnCl2 : compound 6) |
Time (h) | Product mass (g) | Yield (%) |
|---|---|---|---|---|
| 1 | 3 : 1 | 8 | 1.35 | 81.2 |
| 2 | 4 : 1 | 3 | 1.45 | 87.3 |
| 3 | 5 : 1 | 3 | 1.37 | 82.5 |
| 4 | 6 : 1 | 3 | 1.39 | 83.7 |
| Entry | Base catalyst | Time (h) | Product mass (g) | Yield (%) |
|---|---|---|---|---|
| 1 | CH3ONa | 6 | 1.90 | 86.7 |
| 2 | t-BuOK | 6 | 1.74 | 79.4 |
| 3 | K2CO3 | 10 | 1.43 | 65.3 |
| 4 | Na2CO3 | 10 | 1.46 | 66.6 |
| Entry | Molar Ratio of Compound 8 : NaBH4 |
Time (h) | Yield (%) |
|---|---|---|---|
| 1 | 1:2 | 14 | 76.1 |
| 2 | 1:3 | 9 | 78.6 |
| 3 | 1:4 | 6 | 86.7 |
| 4 | 1:5 | 6 | 86.5 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).